Prevention of Stroke in Patients with Silent Cerebrovascular Disease
Stroke 48:e44-e71, Smith, E.E.,et al, 2017
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
NEJM 378:2191-2201, Hart, R.G.,et al, 2018
Stroke
Lancet 389:641-654, Hankey, G.J., 2017
Microbleeds are Associated with Subsequent Hemorrhagic and Ischemic Stroke in Healthy Elderly Individuals
Stroke 42:1867-1871, Bokura, H.,et al, 2011
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Role of COL4A1 in Small-Vessel Disease and Hemorrhagic Stroke
NEJM 354:1489-1496, Gould,D.B.,et al, 2006
Effect of Treating Isolated Systolic Hypertension on the Risk of Developing Various Types and Subtypes of Stroke
JAMA 284:465-471, Perry,Jr.,H.M. et al, 2000
Mechanisms of Second and Further Strokes
JNNP 64:771-776, 7161998., Yamamoto,H.&Bogousslavsky,J., 1998
Importance of Hemodynamic Factors in the Prognosis of Symptomatic Carotid Occlusion
JAMA 280:1055-1060, 10931998., Grubb,R.L.,et al, 1998
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997
Carotid Endarterectomy and Prevention of Cerebral Ischemia in Symptomatic Carotid Stenosis
JAMA 266:3289-3294, 33321991., Mayberg,M.R.,et al, 1991
Stroke-1989 Recommendations on Stroke Prevention
Diagnosis, and Therapy, Report of the WHO Force on Stroke and CV Disorders, Stroke 20:1407-143189., , 1989
Controversies in the Management of Cerebral Vascular Disease
Neurol 38:1609-1616, Scheinberg,P., 1988
Alcohol & Hemorrhagic Stroke, The Honolulu Heart Program
JAMA 255:2311-2314, Donahue,R.P.,et al, 1986
Contemporary Trends in the Nationwide Incidence of Primary Intracerebral Hemorrhage
Stroke 53:e70-e74, Bako, A.T.,et al, 2022
Cancer and Embolic Stroke of Undetermined Source
Stroke 52:1121-1130, Navi,B.B.,et al, 2021
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events with Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients with Atrial Fibrillation with a History of Intracranial Hemorrhage
JAMA Network Open 3:e206424, Tsai, C.T.,et al, 2020
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Implantable Cardiac Monitoring in the Secondary Prevention of Cryptogenic Stroke
Ann Neurol 88:946-955, Triantafyllou, S.,et al, 2020
Ischemic Stroke and Internal Carotid Artery Web
Stroke 50:e31-e34, Mc Grory, B.,et al, 2019
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
NEJM 379:215-225, 291, Johnston, S.C.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Optimal Timing of Anticoagulant Treatment after Intracerebral Hemorrhage in Patients with Atrial Fibrillation
Stroke 48:314-320, Pennlert, J.,et al, 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant
J Stroke Cerebrovasc Dis 26:2976-2980, Nam, K.W.,et al, 2017
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
The Value of Transesophageal Echocardiography for Embolic Strokes of Undetermined Source
Neuol 87:988-995, Katsanos, A.H.,et al, 2016
Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke
Stroke 47:2380-2385, Yong, J.H.E.,et al, 2016
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
Stroke 46:2032-2060, Hemphill, J.C.,et al, 2015
Nontraditional Risk Factors for Ischemic Stroke
Stroke 46:3572-3578, Bang, O.Y.,et al, 2015
Percutaneous Left Atrial Appendage Closure:Technical Aspects and Prevention of Periprocedural Complications with the Watchman Device
Workd J Cardiol 26:65-75, Mobius-Winkler,S.,et al, 2015
Summary of Evidence-Based Guideline Update: Prevention of Stroke in Nonvalvular Atrial Fibrillation
Neurol 82:716-724, Culebras, A.,et al, 2014
Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients with Atrial Fibrillation
JAMA 311:1150-1151, Bruins Slot, K.M.H. & Berge, E., 2014
Cryptogenic Stroke and Underlying Atrial Fibrillation
NEJM 370:2478-2486,2532, Sanna, T.,et al, 2014
Atrial Fibrillation in Patients with Cryptogenic Stroke
NEJM 370:2467-2477,2532, Gladstone, D.J.,et al, 2014
Cerebrovascular Events in 21 105 Patients with Atrial Fibrillation Randomized to Edoxaban Versus Warfarin
Stroke 45:2372-2378, Giugliano, R.P.,et al, 2014
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Oral Anticoagulants and the Risk of Intracranial Hemorrhage
JAMA 312:2562-2563, Vespa, P.M., 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Faxtor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients with Atrial Fibrillation
Stroke 44:e165-e167, Bruins, K.M.H., & Berge, E., 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012